-
肺癌是目前发病率与病死率最高的恶性肿瘤,死亡率高主要是由于绝大部分病人确诊时已属中晚期,5年生存率极低[1]。因此,肺癌的早期诊断和有效的治疗方法是改善预后和提高生存率的关键。近年来,一些研究发现微小RNA(microRNA,miRNA)能调节多种肿瘤的发生、发展及转移等[2]。循环miRNAs可作为肺癌诊断标记物[3],还可在预测肿瘤治疗反应、疗效评价[4]及预后[5]等方面起到重要作用。
miRNA广泛存在于真核生物中,是一种在进化中高度保守的短链非编码RNA[6]。let-7是人体内第一个被发现的miRNA,包含13个成员:let-7-a-1/2/3,let-7-b,let-7-c,let-7-d,let-7-e,let-7-f-1/2,let-7-g,let-7-i,mir-98和mir-202[7]。let-7家族是目前研究最多的miRNA之一,研究[8-10]发现其在多种肿瘤中表达下调,可能作为癌基因或抑癌基因参与肿瘤的发生、发展。关于let-7与肿瘤的研究大多集中在let-7a和let-7b上,关于let-7c的研究较少,而且let-7a1和let-7c共同在肺癌中的研究,至今未见报道。
本研究通过检测肺癌组织、癌旁正常组织和良性肺疾病组织中let-7a1和let-7c基因的表达,分析两者与肺癌发生、发展的相关性,探讨其在肺癌发生中可能的分子机制。
-
肺腺癌病理显示肿瘤结节状生长,浸润周围肺组织;低倍镜下癌细胞呈不规则腺管状排列,在胶原纤维间浸润性生长。免疫组织化学结果显示癌细胞表达TTF1、CK7、NapsionA(见图 2)。肺鳞癌病理显示不规则结节状生长,与周围肺组织界限不清;低倍镜下癌细胞呈大小不一的巢团状生长,可见小的角化珠及细胞内角化,间质胶原化。免疫组织化学结果显示瘤细胞表达p63、p40(见图 3)。
-
荧光定量PCR扩增曲线呈较为光滑的S型,均在30个循环以前出现扩增信号,结果较为可靠;由于产物序列不同,溶解曲线荧光信号主峰基本集中在80~90 ℃和78~88 ℃,其前有小的杂峰,考虑为复空中底物浓度过低所至引物二聚体的形成(见图 4~7)。
-
肺癌组织中let-7a1和let-7c的相对表达量均低于癌旁正常组织和良性肺疾病组织(P < 0.05);癌旁正常组织中let-7a1和let-7c的相对表达量均低于良性肺疾病组织(P < 0.05)(见表 1)。
分组 n let-7a1 let-7c 肺癌组织 44 0.93± 0.46*# 1.16± 0.76*# 癌旁正常组织 44 1.18±0.54* 1.59±0.88* 良性肺疾病组织 9 1.38±0.54 1.81±0.63 F — 4.39 4.30 P — < 0.05 < 0.05 MS组内 — 0.026 0.652 q检验:与良性肺疾病组织比较*P < 0.05;与癌旁组织比较#P < 0.05 表 1 肺癌组织、癌旁正常组织和良性肺疾病组织中let-7a1、let-7c基因的表达比较(x±s)
-
let-7a和let-7c基因在肺鳞癌和腺癌中的相对表达量差异均无统计学意义(P>0.05)(见表 2);在肺鳞癌和腺癌旁正常组织中的相对表达量差异也均无统计学意义(P>0.05)(见表 3)。
分组 n let-7a1 let-7c 鳞癌 21 1.01±0.41 1.02±0.83 腺癌 23 0.86±0.49 1.07±0.90 t — 1.12 0.86 P — >0.05 >0.05 表 2 let-7a1和let-7c基因在不同病理类型肺癌组织中的表达比较(x±s)
分组 n let-7a1 let-7c 鳞癌旁正常组织 21 1.33±0.62 1.61±0.74 腺癌旁正常组织 23 1.05±0.41 1.57±1.00 t — 1.78 0.16 P — >0.05 >0.05 表 3 let-7a和let-7c基因在不同病理类型肺癌旁正常组织中的表达比较(x±s)
-
let-7a1表达与分化程度、吸烟和TNM分期有关(P < 0.05~P < 0.01),与淋巴结有无转移无关(P>0.05)。let-7c表达与淋巴结转移、分化程度有关(P < 0.01),与吸烟、TNM分期无关(P>0.05)(见表 4)。
临床特征 n let-7a1 let-7c 淋巴结转移 有 30 0.90±0.43 0.80±0.31 无 14 1.00±0.52 1.95±0.86 t — 0.66 6.54 P — >0.05 < 0.01 分化程度 低 4 0.35±0.11 1.04±0.30 中 27 0.79±0.28* 0.92±0.51 高 13 1.42±0.39*# 1.71±1.02# F — 26.58 5.85 P — < 0.01 < 0.01 吸烟 有 23 0.63±0.21 1.04±0.52 无 21 1.27±0.41 1.29±0.96 t — 6.64 1.08 P — < 0.01 >0.05 TNM分期 ≤Ⅲa期 39 0.99±0.45 1.20±0.80 Ⅲb期 5 0.50±0.28 0.87±0.38 t — 2.41 0.91 P — < 0.05 >0.05 q检验:与低分化组比较*P < 0.05;与中分化组比较#P < 0.05 表 4 let-7a-1和let-7c基因与各临床相关指标之间的关系(x±s)
let-7a1和let-7c在非小细胞肺癌中的表达及临床意义
Expression and clinical significance of let-7a1 and let-7c in non-small cell lung cancer
-
摘要:
目的探讨人类微小RNA let-7a1和let-7c在肺癌组织中的表达及与临床病理特征之间的关系。 方法收集53例肺组织手术标本及临床资料,其中包括肺癌组织44例(收集其癌组织和癌旁正常组织)和良性肺疾病组织9例。并收集病人吸烟史、肿瘤TNM分期、病理分化程度及有无淋巴结转移等。采用Trizol法提取总RNA,采用荧光定量PCR检测let-7a1和let-7c的表达,分析其在肺癌组织、癌旁正常组织及良性肺疾病组织中的表达差异及与临床特征的关系。 结果肺癌组织中let-7a1和let-7c的相对表达量均低于癌旁正常组织和良性肺疾病组织(P < 0.05);癌旁正常组织中let-7a1和let-7c的相对表达量均低于良性肺疾病组织(P < 0.05)。let-7a1表达与分化程度、吸烟和TNM分期有关(P < 0.05~P < 0.01),与淋巴结有无转移无关(P>0.05)。let-7c表达与淋巴结转移、分化程度有关(P < 0.01),与吸烟、TNM分期无关(P>0.05)。 结论let-7a1和let-7c基因在肺癌组织中相对表达量降低,并且随临床分期进展、淋巴结转移呈明显下降趋势,提示两者与肺癌的发生、发展及转移密切相关,let-7a1和let-7c可能成为肺癌早期诊断生物标志因子,并可能成为肺癌的靶向治疗新的靶点,为高危人群的早期干预提供实验依据。 Abstract:ObjectiveTo investigate the expression of human microRNA let-7a1 and let-7c in lung cancer tissues and its relationship with clinicopathological features. MethodsThe surgical specimens and clinical data of 53 cases of lung tissue were collected, including 44 cases of lung cancer used to collect cancer tissue and paracancerous normal tissue, and 9 cases of benign lung disease tissue.The smoking history, TNM stage, pathological differentiation and lymph node metastasis were collected.The total RNA was extracted by Trizol method, and the expression of let-7a1 and let-7c was detected by fluorescence quantitative PCR.The difference of let-7a1 and let-7c expression in lung cancer tissue, paracancerous normal tissue and benign lung disease tissue, and its relationship with clinical features were analyzed. ResultsThe relative expression of let-7a1 and let-7c in lung cancer tissue was lower than that in paracancerous normal tissue and benign lung disease tissue(P < 0.05), and the relative expression of let-7a1 and let-7c in paracancerous normal tissue was lower than that in benign lung disease tissue(P < 0.05).The expression of let-7a1 was related to differentiating degree, smoking and TNM stage (P < 0.05 to P < 0.01), but was not related to smoking and TNM stage (P>0.05).The expression of let-7c was related to lymph node metastasis and differentiating degree (P < 0.01), but was not related to smoking and TNM stage (P>0.05). ConclusionsThe relative expression of let-7a1 and let-7c genes in lung cancer tissue decreases, and exhibits decreasing trend with the progress of clinical stage and lymph node metastasis, which suggests that let-7a1 and let-7c are closely related to the occurrence, development and metastasis of lung cancer.Let-7a1 and let-7c may become biomarkers for early diagnosis of lung cancer, and become new targets for targeted therapy of lung cancer, to provide experimental basis for early intervention of high-risk groups. -
Key words:
- lung neoplasms /
- microRNA /
- let-7a1 /
- let-7c
-
表 1 肺癌组织、癌旁正常组织和良性肺疾病组织中let-7a1、let-7c基因的表达比较(x±s)
分组 n let-7a1 let-7c 肺癌组织 44 0.93± 0.46*# 1.16± 0.76*# 癌旁正常组织 44 1.18±0.54* 1.59±0.88* 良性肺疾病组织 9 1.38±0.54 1.81±0.63 F — 4.39 4.30 P — < 0.05 < 0.05 MS组内 — 0.026 0.652 q检验:与良性肺疾病组织比较*P < 0.05;与癌旁组织比较#P < 0.05 表 2 let-7a1和let-7c基因在不同病理类型肺癌组织中的表达比较(x±s)
分组 n let-7a1 let-7c 鳞癌 21 1.01±0.41 1.02±0.83 腺癌 23 0.86±0.49 1.07±0.90 t — 1.12 0.86 P — >0.05 >0.05 表 3 let-7a和let-7c基因在不同病理类型肺癌旁正常组织中的表达比较(x±s)
分组 n let-7a1 let-7c 鳞癌旁正常组织 21 1.33±0.62 1.61±0.74 腺癌旁正常组织 23 1.05±0.41 1.57±1.00 t — 1.78 0.16 P — >0.05 >0.05 表 4 let-7a-1和let-7c基因与各临床相关指标之间的关系(x±s)
临床特征 n let-7a1 let-7c 淋巴结转移 有 30 0.90±0.43 0.80±0.31 无 14 1.00±0.52 1.95±0.86 t — 0.66 6.54 P — >0.05 < 0.01 分化程度 低 4 0.35±0.11 1.04±0.30 中 27 0.79±0.28* 0.92±0.51 高 13 1.42±0.39*# 1.71±1.02# F — 26.58 5.85 P — < 0.01 < 0.01 吸烟 有 23 0.63±0.21 1.04±0.52 无 21 1.27±0.41 1.29±0.96 t — 6.64 1.08 P — < 0.01 >0.05 TNM分期 ≤Ⅲa期 39 0.99±0.45 1.20±0.80 Ⅲb期 5 0.50±0.28 0.87±0.38 t — 2.41 0.91 P — < 0.05 >0.05 q检验:与低分化组比较*P < 0.05;与中分化组比较#P < 0.05 -
[1] TORRE LA, SIEGEL RL, JEMAL A. Lung cancer statistics[J]. Adv Exp Med Biol, 2016, 893: 1. [2] REDDY KB. MicroRNA(miRNA) in cancer[J]. Cancer Cell Int, 2015, 15(1): 38. doi: 10.1186/s12935-015-0185-1 [3] WANG C, DING M, XIA M, et al. A five-miRNA panel identified from a multicentric case-control study serves as a novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients[J]. Bio Medicine, 2015, 2(10): 1377. doi: 10.1016/j.ebiom.2015.07.034 [4] FRANCHINA T, AMODEO V, BRONTE G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer[J]. J Cell Physiol, 2014, 229(1): 97. [5] MATIKAS A, SYRIGOS KN, AGELAKI S. Circulating biomarkers in non-small-cell lung cancer: current status and future challenges[J]. Clin Lung Cancer, 2016, 17(6): 507. doi: 10.1016/j.cllc.2016.05.021 [6] STEFANI G, SLACK FJ. Small non-coding RNAs in animal development[J]. Nat Rev Mol Cell Bio, 2008, 9(3): 219. doi: 10.1038/nrm2347 [7] BOYERINAS B, PARK SM, HAU A, et al. The role of let-7 in cell differentiation and cancer[J]. Endocrine-Related Cancer, 2010, 17(1): F19. doi: 10.1677/ERC-09-0184 [8] YE Y, LI X, YANG Q, et al. The role of microRNA in human lung squamous cell carcinoma[J]. Cancer Genet Cytogenet, 2010, 200(2): 127. doi: 10.1016/j.cancergencyto.2010.03.014 [9] ZHONG Z, DONG Z, YANG L, et al. Inhibition of proliferation of human lung cancer cells by green tea catechins is mediated by upregulation of let-7[J]. Exp Ther Med, 2012, 4(2): 267. doi: 10.3892/etm.2012.580 [10] ZHAN M, QU Q, WANG G, et al. Let-7c inhibits NSCLC cell proliferation by targeting HOXA1[J]. APJCP, 2013, 14(1): 387. doi: 10.7314/APJCP.2013.14.1.387 [11] 中国临床肿瘤学会血管靶向治疗专家委员会, 非小细胞肺癌专家委员会, 非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)[J]. 中国肺癌杂志, 2019, 22(7): 401. [12] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492 [13] 何圆, 尤长宣. 非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2014, 17(3): 277. [14] 张娣, 黄架旗, 张初峰, 等. PD-1/PD-L1免疫检查点抑制剂在肺癌中的研究进展[J]. 中国肺癌杂志, 2019, 22(6): 366. [15] 尚学琴, 阎婷婷, 杨眉, 等. 肺癌组织中Let-7的表达及意义[J]. 广东医学, 2018, 39(7): 983. [16] 董峰, 马君俊, 孙晶, 等. miR-124a、let-7表达与胃癌临床病理特征和化疗疗效的相关性[J]. 现代生物医学进展, 2018, 18(24): 4643. [17] 喻箴, 肖明耀, 崔明, 等. Let-7在正常乳腺组织和乳腺癌组织中的表达[J]. 昆明医科大学学报, 2016, 37(7): 19. [18] FASSINA A, CAPPELLESSO R, FASSAN M. Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling[J]. Chest, 2011, 140(5): 1305. doi: 10.1378/chest.11-0708 [19] ZHAO B, HAN H, CHEN J, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3[J]. Cancer Letters, 2014, 342(1): 43. doi: 10.1016/j.canlet.2013.08.030 [20] 耿淼, 潘静坤, 罗芸, 等. miRNA Let-7与乳腺癌预后的相关性分析[J]. 局解手术学杂志, 2019, 28(1): 1. [21] ZHU X, WU L, YAO J, et al. MicroRNA let-7c inhibits cell proliferation and induces cell cycle arrest by targeting CDC25A in human hepatocellular carcinoma[J]. PLoS One, 2015, 10(4): e0124266. doi: 10.1371/journal.pone.0124266 [22] IZZOTTI A, CALIN GA, ARRIGO P, et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke[J]. Faseb J, 2009, 23(3): 806. doi: 10.1096/fj.08-121384 [23] 李玉梅, 刘静, 周争光, 等. 培美曲塞与吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的对比研究[J]. 蚌埠医学院学报, 2018, 43(6): 719. [24] YANG Z, LIU C, WU H, et al. CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29[J]. BMC Cancer, 2019, 19(1): 948. doi: 10.1186/s12885-019-6194-z [25] MEIRAV S, ANNABELLE B, MAUD-EMMANUELLE G, et al. Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo[J]. Mol Ther Nucleic Acids, 2020, 19: 267. doi: 10.1016/j.omtn.2019.11.008 [26] ZHOU Y, LIANG H, LIAO Z, et al. MIR-203 enhances let-7 biogenesis by targeting LIN28B to suppress tumor growth in lung cancer[J]. Sci Rep, 2017, 7: 42680. doi: 10.1038/srep42680 [27] YIN J, HU W, PAN L, et al. Let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer(Article)[J]. Oncol Rep, 2019, 42(2): 495. doi: 10.3892/or.2019.7197 [28] CHEN Y, XIE C, ZHENG X, et al. LIN28/let-7/PD-L1 pathway as a target for cancer immunotherapy[J]. Cancer Immunol Res, 2019, 7(3): 487. doi: 10.1158/2326-6066.CIR-18-0331 [29] GILLES ME, SLACK FJ. Let-7 microRNA as a potential therapeutic target with implications for immunotherapy[J]. Expert Opin Ther Targets, 2018, 22(11): 929. doi: 10.1080/14728222.2018.1535594 [30] LI XX, DI X, CONG S, et al. The role of let-7 and HMGA2 in the occurrence and development of lung cancer: a systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8353. doi: 10.26355/eurrev_201812_16533